Discovery of new heat shock protein 90 inhibitors using virtual co-crystallized pharmacophore generation

References

• Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003;3:301–23
   PubMed Web of Science ®Google Scholar
• Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006;6:1205–14
   PubMed Web of Science ®Google Scholar
• Chiosis G, Rodina A, Moulick K. Emerging Hsp90 inhibitors: from discovery to clinic. Anticancer Agents Med Chem 2006;6:1–8
   PubMedGoogle Scholar
• Christopher R, Edwards W. Davidson’s principles and practice of medicine. In: Bouchier IA, ed. Oncology. Chapter seven, 16th ed. Edinburgh, UK: ELBS Publisher; 1991
   Google Scholar
• Neckers L, Mollapour M, Tsutsumi S. The complex dance of the molecular chaperone Hsp90. Trends Biochem Sci 2009;34:223–6
   PubMed Web of Science ®Google Scholar
• Xiao L, Lu X, Ruden DM. Effectiveness of Hsp90 inhibitors as anti-cancer drugs. Mini Rev Med Chem 2006;6:1137–43
   PubMed Web of Science ®Google Scholar
• Al-Sha’er MA, Taha MO. Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors. J Chem Inf Model 2010;50:1706–23
   PubMed Web of Science ®Google Scholar
• Sheikha GA, Al-Sha'er MA, Taha MO. Some sulfonamide drugs inhibit ATPase activity of heat shock protein 90: investigation by docking simulation and experimental validation. J Enzyme Inhib Med Chem 2010;26:603–9
   PubMed Web of Science ®Google Scholar
• Al-Sha’er MA, Taha MO. Rational exploration of new pyridinium-based HSP90α inhibitors tailored to thiamin structure. Med Chem Res 2012;21:487–510
   Web of Science ®Google Scholar
• Al-Sha'er MA, Taha MO. Application of docking-based comparative intermolecular contacts analysis for validating Hsp90α docking studies and subsequent in silico screening for inhibitors. J Mol Modeling 2012;18:4843–63
   PubMed Web of Science ®Google Scholar
• Al-Sha'er MA. Evaluation of miscellaneous heat shock protein (Hsp90) inhibitors using different methodologies. Der Pharma Chemical 2013;5:173–83
   Google Scholar
• Christopher A, Boris AK, Brian SJ. Development and optimization of a useful assay for determining Hsp90_s inherent ATPase activity. Bioorg Med Chem 2006;14:1134–42
   PubMed Web of Science ®Google Scholar
• Avila C, Hadden MK, Ma Z, et al. High-throughput screening for Hsp90 ATPase inhibitors. Bioorg Med Chem Lett 2006;16:3005–8
   PubMed Web of Science ®Google Scholar
• Chiosis G, Lucas B, Shtil A, et al. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem 2002;10:3555–64
   PubMed Web of Science ®Google Scholar
• Neckers L. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Curr Top Med Chem 2006;6:1163–71
   PubMed Web of Science ®Google Scholar
• Hideyuki O, Masami K, Yuichi T, et al. Conformational significance of EH21A1-A4, phenolic derivatives of Geldanamycin, for Hsp90 inhibitory activity. Bioorg Med Chem Lett 2008;18:1577–80
   PubMed Web of Science ®Google Scholar
• Kasibhatla SR, Hong K, Biamonte MA, et al. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J Med Chem 2007;50:2767–78
   PubMed Web of Science ®Google Scholar
• Hwangseo P, Yun-Jung K, Ji-Sook H. A novel class of hsp90 inhibitors isolated by structure-based virtual screening. Bioorg Med Chem Lett 2007;17:6345–9
   PubMed Web of Science ®Google Scholar
• Barril X, Beswick M, Collier A, et al. 4-Amino derivatives of the Hsp90 inhibitor CCT018159. Bioorg Med Chem Lett 2006;16:2543–8
   PubMed Web of Science ®Google Scholar
• Barril X, Brough P, Drysdale M, et al. Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005;15:5187–91
   PubMed Web of Science ®Google Scholar
• Jeffrey RH, Chang P, Andrew MP, et al. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chem Biol Drug 2007;70:1–12
   PubMed Web of Science ®Google Scholar
• Sakkiah S, Thangapandian S, John S, et al. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. Eur J Med Chem 2010;45:2132–40
   PubMed Web of Science ®Google Scholar
• Chen CY-C. Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/HSP90 dual-targeted inhibitors. J Taiwan Inst Chem E 2010;41:143–9
   Web of Science ®Google Scholar
• Stebbins CE, Russo AA, Schneider C, et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239–50
   PubMed Web of Science ®Google Scholar
• Levit A, Yarnitzky T, Wiener A, et al. Modeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs. PLoS One 2011;6:e27990
   PubMed Web of Science ®Google Scholar
• Protein Data Bank, PDB; 2016. Available from: www.rcsb.org
   Google Scholar
• Accelrys Software Inc., CATALYST 4.11 Users’; Manual. San Diego, CA: Accelrys Software Inc.;2005
   Google Scholar
• Sutter J, Güner O, Hoffmann R, et al. International university line. In: Güner OF, ed. Pharmacophore perception, development, and use in drug design. La Jolla, CA: International University Line; 2000:501–11
   Google Scholar
• Accelrys Software Inc., CERIUS2, QSAR Users Manual, version 4.10. San Diego, CA: Accelrys Inc.; 2005: 43–88, 221–235, 237–250
   Google Scholar
• Kurogi Y, Güner OF. Pharmacophore modeling and three dimensional database searching for drug design using catalyst. Curr Med Chem 2001;8:1035–55
   PubMed Web of Science ®Google Scholar
• Poptodorov K, Luu T, Langer T, Hoffmann R. Pharmacophores and pharmacophores searches. In: Hoffmann RD, ed. Methods and principles in medicinal chemistry. Weinheim, Germany: Wiley-VCH; 2006, 2:17–47
   Google Scholar
• Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity a rapid access to atomic charges. Tetrahedron 1980;36:3219–28
   Web of Science ®Google Scholar
• Accelrys Software Inc., CERIUS2 4.10. LigandFit User Manual. San Diego, CA: Accelrys Inc.; 2000
   Google Scholar
• Venkatachalam CM, Jiang X, Oldfield T, Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 2003;21:289–307
   PubMed Web of Science ®Google Scholar
• Triballeau N, Acher F, Brabet I, et al. Virtual screening workflow development guided by the “Receiver Operating Characteristic” curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 2005;48:2534–47
   PubMed Web of Science ®Google Scholar
• Irwin JJ, Shoichet BK. ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005;45:177–82
   PubMed Web of Science ®Google Scholar
• Brough PA, Aherne W, Barril X, et al. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008;51:196–218
   PubMed Web of Science ®Google Scholar
• McDonald E, Jones K, Brough PA, et al. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr Top Med Chem 2006;6:1193–203
   PubMed Web of Science ®Google Scholar
• Gopalsamy A, Shi M, Golas J, et al. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90. J Med Chem 2008;51:373–5
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3–26
   PubMed Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615–23
   PubMed Web of Science ®Google Scholar
• CCT018159, Tocris Bioscience, Bristol, BS11 9QD, UK; 2016. Available from: https://www.tocris.com/dispprod.php?ItemId=151522#.V6O01jsrLbI
   Google Scholar